At a glance
- Originator Dainippon Pharmaceutical
- Class Anti-ischaemics; Antiepileptic drugs; Benzoxepins; Neuroprotectants
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cerebrovascular disorders; Epilepsy; Hypertension
Most Recent Events
- 05 Jun 2001 Discontinued-Preclinical for Hypertension in Japan (Unknown route)
- 14 Jun 2000 Discontinued-Preclinical for Cerebrovascular disorders in Japan (Unknown route)
- 14 Jun 2000 Discontinued-Preclinical for Epilepsy in Japan (Unknown route)